A nurse shows vials of the dengue vaccine Dengvaxia, developed by French medical giant Sanofi Pasteur, at an elementary school in Manila.
Concerned over the health of close to some 500,000 schoolchildren administered with the vaccine Dengvaxia, Senator Richard J. Gordon has expressed alarm over reports that the manufacturer Sanofi has acknowledged its dengue vaccine poses risks to certain recipients.
In what many described as a major Aha! Moment, Sanofi disclosed Thursday that, “for individuals who have not been previously infected by dengue virus, vaccination should not be recommended.”
The situation poses a big and deep quandary, especially for those responsible in the formulation and execution of this mass dengue vaccination program intended to cover one million children nine years old and up.
Early warning